Bottom line
In late 2023, the European Medicines Agency (EMA) launched a safety review of GLP-1 medications after reports of suicidal ideation and self-harm in patients taking semaglutide and liraglutide. The FDA followed with its own evaluation. Both agencies completed their reviews in 2024 and reached the same conclusion:
The available evidence does not establish a causal link between GLP-1 medications and suicidal ideation or depression. The FDA did not add new warnings to the labeling. The EMA reached a similar finding but recommended continued monitoring.
That said, the relationship between GLP-1s and mental health is more nuanced than "no signal found." Here's what we know, what we don't, and what matters for patients.
What triggered the concern
Several overlapping signals raised the question:
Adverse event reports. The FDA Adverse Event Reporting System (FAERS) received reports of suicidal ideation, depression, and anxiety in patients taking GLP-1s. FAERS is a passive reporting system — anyone can submit a report, and the existence of a report does not establish causation. The volume of GLP-1 reports was consistent with the massive increase in prescriptions (tens of millions of patients), and the reporting rate was not disproportionate when adjusted for the size of the treated population.
Media amplification. Individual patient stories of mood changes on GLP-1s were widely covered. These stories are real and worth taking seriously — but they are anecdotal evidence, not epidemiological signal.
Biological plausibility. GLP-1 receptors exist in brain regions involved in mood regulation (the hippocampus, amygdala, and prefrontal cortex). It is biologically plausible that modulating GLP-1 signaling could affect mood, even if the net effect is not necessarily negative.
What the clinical trials show
The most useful data comes from the large randomized controlled trials, where mood and psychiatric outcomes were tracked prospectively:
STEP trials (semaglutide): The Columbia Suicide Severity Rating Scale (C-SSRS) was administered at baseline and throughout the trials. No statistically significant increase in suicidal ideation or behavior was observed in the semaglutide arms versus placebo.
SELECT trial (semaglutide, cardiovascular outcomes): Over 17,600 patients followed for a mean of 40 months. No increase in depression, suicidal ideation, or psychiatric adverse events in the semaglutide arm. This is the largest and longest GLP-1 dataset available.
SURMOUNT trials (tirzepatide): PHQ-9 (depression screener) was collected. Tirzepatide arms showed slight improvements in depressive symptoms versus placebo — consistent with the well-established association between weight loss and improved mood in patients with obesity.
Pooled meta-analyses (published 2024-2025): Multiple systematic reviews pooling data across GLP-1 trials found no increased risk of depression, anxiety, or suicidal ideation. Some analyses found a modest protective signal — consistent with weight loss improving mental health.
Why some patients do feel worse
The absence of a population-level signal does not mean individual patients can't have meaningful mood changes on a GLP-1. Several mechanisms can explain worsened mood in individual patients:
1. Loss of food as a coping mechanism. For patients who use food to manage stress, anxiety, loneliness, or depression, the sudden reduction in food noise and appetite can remove a primary coping tool without replacing it. The underlying emotional distress surfaces, sometimes intensely.
This is the most commonly cited mechanism by psychiatrists and psychologists working with GLP-1 patients. It is not a drug side effect per se — it is the unmasking of an emotional pattern that food was managing.
2. Rapid body change and identity disruption. Losing 15-25% of body weight in under a year is a dramatic physical transformation. Patients report complicated feelings about their changing body: positive reactions mixed with grief for the body they knew, disrupted relationships (people treat them differently), and sometimes a sense of identity loss.
3. Nutritional deficits. Severe caloric restriction, particularly inadequate protein, B vitamins, iron, and omega-3 fatty acids, is independently associated with mood deterioration. Patients on GLP-1s who are eating very little may develop nutritional deficits that affect brain chemistry.
4. GI distress and fatigue. Persistent nausea, reflux, or fatigue — particularly during dose titration — can meaningfully worsen quality of life and contribute to low mood.
5. Pre-existing psychiatric conditions. Patients with depression, anxiety, bipolar disorder, or PTSD may experience fluctuations that coincide with (but are not caused by) GLP-1 initiation. Correlation in timing is not causation.
What to watch for
If you're on or starting a GLP-1, these are the signals worth flagging to your prescriber:
- New or worsening depressive symptoms (persistent sadness,
loss of interest, hopelessness, fatigue) that don't improve within 2-3 weeks
- Suicidal thoughts, even fleeting ones — call your prescriber
or go to an ER. Call 988 (Suicide & Crisis Lifeline) if you need immediate support.
- Increased anxiety that wasn't present before the medication
or that is meaningfully worse
- Significant sleep changes (insomnia or hypersomnia) not
explained by other factors
- Social withdrawal
- Marked irritability or mood swings
Most prescribers recommend baseline mood screening (PHQ-9 for depression, GAD-7 for anxiety) before starting a GLP-1 and repeat screening at 3 and 6 months. If your prescriber doesn't offer this, ask for it.
The behavioral health companion case
An emerging standard of care in obesity medicine: behavioral health support alongside GLP-1 therapy. The rationale is straightforward:
- Rapid weight loss disrupts coping patterns, body image, and
relationships
- Food noise reduction removes a familiar (if unhealthy)
comfort mechanism
- Patients benefit from new tools to manage the emotions that
food was previously managing
Some telehealth programs include behavioral health as standard. Others offer it as an add-on. If your program doesn't include it and you have any history of mood difficulties, depression, anxiety, or disordered eating, consider adding a therapist (ideally one familiar with weight management) independently.
GLP-1s and existing psychiatric medications
GLP-1s have no known direct drug interactions with SSRIs, SNRIs, benzodiazepines, mood stabilizers, or antipsychotics. However, two practical considerations:
1. Absorption changes for oral medications. GLP-1s slow gastric emptying, which can alter the absorption profile of oral medications. For most psychiatric drugs with wide therapeutic windows, this is not clinically significant. For medications with narrow therapeutic windows (lithium, some anticonvulsants), your prescriber may want to monitor levels more closely during GLP-1 titration.
2. Weight-affecting psychiatric medications. Many psychiatric medications cause weight gain (olanzapine, quetiapine, mirtazapine, valproic acid, some SSRIs). GLP-1s can counteract medication-induced weight gain. If a patient is on both, the net weight effect depends on the balance of forces. Some psychiatrists are now prescribing GLP-1s specifically to offset antipsychotic-induced weight gain, with growing evidence supporting this approach.
What the science may eventually show
Several large-scale studies are ongoing:
- Post-marketing surveillance studies specifically tracking
psychiatric outcomes in GLP-1 patients
- Trials of semaglutide specifically for alcohol use disorder
and addiction, which will generate extensive mental health data
- Real-world evidence studies using large insurance claims
databases to compare psychiatric outcomes in GLP-1 users versus matched controls
The preliminary signal from most of this work is neutral to slightly positive — meaning GLP-1 patients as a population show equal or slightly better mental health outcomes than matched non-users, likely driven by the mental health benefits of weight loss.
What to ask your prescriber
- "Can we do a baseline PHQ-9 and GAD-7 before I start?"
- "How will we monitor my mood over the first 6 months?"
- "Should I adjust any of my current psychiatric medications
during titration?"
- "Do you recommend behavioral health support alongside GLP-1
therapy?"
- "What's your threshold for pausing or adjusting the GLP-1
if I report mood changes?"
What this means for you
The evidence does not support avoiding GLP-1s because of mental health concerns. The evidence does support paying attention to your mental health while on a GLP-1 — the same way you pay attention to GI side effects, protein intake, and weight trends.
If you have a history of depression, anxiety, or disordered eating, you're not at higher risk of a GLP-1 adverse event — but you may benefit from more structured monitoring and concurrent behavioral health support. The weight loss itself is overwhelmingly positive for mental health. The transition period — losing food as comfort, adjusting to a changing body — is where the work is.